MCID: PRT037
MIFTS: 49

Pertussis

Categories: Infectious diseases, Rare diseases, Respiratory diseases, Smell/Taste diseases

Aliases & Classifications for Pertussis

MalaCards integrated aliases for Pertussis:

Name: Pertussis 12 73 20 58 3 15 70
Whooping Cough 12 73 20 58 42 3 15 17 32
Bordetella Infections 44 17 70
Whooping Cough Due to Unspecified Organism 70
Bordetella Pertussis Infection 20
Bordetella Infection 12
Wc - Whooping Cough 12

Characteristics:

Orphanet epidemiological data:

58
whooping cough
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1116
MeSH 44 D001885
SNOMED-CT 67 26484003
MESH via Orphanet 45 D014917
ICD10 via Orphanet 33 A37.0 A37.1 A37.8 more
UMLS via Orphanet 71 C0043167 C0043168
Orphanet 58 ORPHA1489
UMLS 70 C0006015 C0043167 C0043168

Summaries for Pertussis

MedlinePlus : 42 Whooping cough is an infectious bacterial disease that causes uncontrollable coughing. The name comes from the noise you make when you take a breath after you cough. You may have choking spells or may cough so hard that you vomit. Anyone can get whooping cough, but it is more common in infants and children. It's especially dangerous for infants. The coughing spells can be so bad that it is hard for infants to eat, drink, or breathe. To make a diagnosis, your doctor may do a physical exam, blood tests, chest x-rays, or nose or throat cultures. Before there was a vaccine, whooping cough was one of the most common childhood diseases and a major cause of childhood deaths in the U.S. Now most cases are prevented by vaccines. If you have whooping cough, treatment with antibiotics may help if given early. Centers for Disease Control and Prevention

MalaCards based summary : Pertussis, also known as whooping cough, is related to diphtheria and tetanus, and has symptoms including fever, pruritus and snoring. An important gene associated with Pertussis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways is Pertussis. The drugs Montelukast and Iron have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, smooth muscle and endothelial.

Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

CDC : 3 Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Pertussis is known for uncontrollable, violent coughing which often makes it hard to breathe. After cough fits, someone with pertussis often needs to take deep breaths, which result in a "whooping" sound. Pertussis can affect people of all ages, but can be very serious, even deadly, for babies less than a year old. The best way to protect against pertussis is by getting vaccinated

Wikipedia : 73 Whooping cough, also known as pertussis or the 100-day cough, is a highly contagious bacterial disease.... more...

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 493)
# Related Disease Score Top Affiliating Genes
1 diphtheria 11.4
2 tetanus 11.3
3 bordetella parapertussis whooping cough 10.9
4 haemophilus influenzae 10.9
5 poliomyelitis 10.9
6 cholera 10.8
7 measles 10.7
8 encephalopathy 10.6
9 disease by infectious agent 10.6
10 hepatitis b 10.6
11 influenza 10.6
12 cyanosis, transient neonatal 10.5
13 allergic disease 10.5
14 mumps 10.5
15 pulmonary hypertension 10.5
16 rubella 10.5
17 allergic encephalomyelitis 10.5
18 thyroid carcinoma, papillary, with papillary renal neoplasia 10.5
19 respiratory failure 10.4
20 bronchiolitis 10.4
21 sudden infant death syndrome 10.4
22 neuroblastoma 10.4
23 hypoglycemia 10.3
24 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
25 febrile seizures 10.3
26 bacterial infectious disease 10.3
27 pneumonia 10.3
28 mediastinitis 10.3
29 hepatitis 10.3
30 glioma 10.3
31 seizure disorder 10.3
32 glial tumor 10.3
33 bronchopneumonia 10.2
34 typhoid fever 10.2
35 bronchitis 10.2
36 encephalitis 10.2
37 cytokine deficiency 10.2
38 autoimmune disease 10.2
39 variola major 10.2
40 smallpox 10.2
41 ige responsiveness, atopic 10.2
42 pain agnosia 10.2
43 hepatitis a 10.2
44 chickenpox 10.2
45 47,xyy 10.2
46 breast-ovarian cancer, familial 2 10.2
47 west syndrome 10.2
48 chlamydia 10.2
49 48,xyyy 10.2
50 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:


fever; pruritus; snoring; coughing

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Iron Approved Phase 4 7439-89-6 23925 29936
3
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
4
Pentetic acid Approved Phase 4 67-43-6
5 Respiratory System Agents Phase 4
6 Anti-Asthmatic Agents Phase 4
7 Hormone Antagonists Phase 4
8 Hormones Phase 4
9 Leukotriene Antagonists Phase 4
10 Immunologic Factors Phase 4
11 Antitoxins Phase 4
12 Gastrointestinal Agents Phase 4
13 Adjuvants, Immunologic Phase 4
14 Aluminum phosphate Phase 4
15 Antacids Phase 4
16 Anti-Ulcer Agents Phase 4
17 Antidotes Phase 4
18 Chelating Agents Phase 4
19 Protective Agents Phase 4
20 Iron Chelating Agents Phase 4
21 Calcium, Dietary Phase 4
22 Anticoagulants Phase 4
23 Vaccines Phase 4
24 Chrysanthemum Phase 4
25 Immunoglobulins Phase 4
26 Antibodies Phase 4
27
Calcium Nutraceutical Phase 4 7440-70-2 271
28
Lactitol Approved, Investigational Phase 3 585-86-4 157355
29
Deferiprone Approved Phase 3 30652-11-0 2972
30 Pharmaceutical Solutions Phase 3
31 Rho(D) Immune Globulin Phase 3
32 Immunoglobulins, Intravenous Phase 3
33 gamma-Globulins Phase 3
34 Hemagglutinins Phase 3
35 PENTA Phase 3
36 Cathartics Phase 3
37 Laxatives Phase 3
38 Somatomedin B Phase 3
39 taxane Phase 3
40 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
41
BCG vaccine Approved, Investigational Phase 1, Phase 2
42
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
43
Aluminum sulfate Approved Phase 1, Phase 2 10043-01-3
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
45
Lecithin Experimental Phase 1, Phase 2 8002-43-5
46 Monophosphoryl lipid A Phase 1, Phase 2
47 Antibodies, Monoclonal Phase 2
48 Soy Bean Phase 1, Phase 2
49 Liver Extracts Phase 1, Phase 2
50 Retinol palmitate Phase 2

Interventional clinical trials:

(show top 50) (show all 303)
# Name Status NCT ID Phase Drugs
1 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
2 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
3 Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study Unknown status NCT02179996 Phase 4
4 Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults Unknown status NCT02555540 Phase 4
5 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
6 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
7 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
8 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
9 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
10 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
11 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
12 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
13 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
14 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
15 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
16 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
17 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Completed NCT02408926 Phase 4
18 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
19 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
20 Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development Completed NCT04543669 Phase 4
21 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
22 Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants Completed NCT01698346 Phase 4
23 Immunological Effects of an Acellular Pertussis Booster Vaccination in Children, Young Adults and Elderly With Different Immunisation Background. An International Study in Finland, the Netherlands and the United Kingdom Completed NCT03697798 Phase 4
24 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
25 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
26 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
27 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
28 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX® Completed NCT00319553 Phase 4
29 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
30 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
31 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
32 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
33 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
34 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
35 Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
36 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
37 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
38 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
39 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
40 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
41 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
42 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
43 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
44 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
45 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
46 Evaluation of GSK Biologicals' Boostrix™ in Healthy Adults, 10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
47 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
48 Double-blind, Randomized, Phase III Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of Three Consecutive Doses of dTpa, or of dTpa-IPV Followed by Two Doses of Td Vaccine , and Compared to Three Consecutive Doses of Td Vaccine Administered to Healthy Adults in a 0,1,6-month Schedule Completed NCT01294605 Phase 4
49 Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix™ (263855) in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
50 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


ERYTHROMYCIN PWDR
Guaifenesin

Cochrane evidence based reviews: bordetella infections

Genetic Tests for Pertussis

Anatomical Context for Pertussis

The Foundational Model of Anatomy Ontology organs/tissues related to Pertussis:

19
Respiratory Tract

MalaCards organs/tissues related to Pertussis:

40
Smooth Muscle, Endothelial, Brain, Pituitary, Neutrophil, Heart, T Cells

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 29059)
# Title Authors PMID Year
1
Clinical impact of respiratory syncytial virus infection on children hospitalized for pertussis. 61 42
33563205 2021
2
Analysis of antibiotic sensitivity and resistance genes of Bordetella pertussis in Chinese children. 61 42
33466172 2021
3
Implementation and adherence of routine pertussis vaccination (DTP) in a low-resource urban birth cohort. 61 42
33384391 2020
4
Phytochemical screening, phenolic and flavonoid contents, antioxidant and cytogenotoxicity activities of Combretum leprosum Mart. (Combretaceae). 61
33494643 2021
5
The impact of provider recommendation on human papillomavirus vaccine and other adolescent vaccines. 61
33074774 2021
6
Pairs of independent nationally representative vaccination coverage surveys conducted within one year of each other: A global overview covering 2000-2019. 61
33644743 2021
7
Serum-borne lipids amplify TLR-activated inflammatory responses. 61
32717772 2021
8
Histone H4 directly stimulates neutrophil activation through membrane permeabilization. 61
32803840 2021
9
Pertussis in Italy: how to protect the "unprotectable"? 61
33121322 2021
10
Effect of a postpartum prescription for pertussis vaccine: a before-and-after study. 61
33421623 2021
11
Infant pertussis and maternal immunity: The curious case of Canada. 61
33750589 2021
12
Pertussis, MMR, and the COVID-19 vaccine: lessons not learned. 61
33675061 2021
13
The knowledge, perceptions, and attitudes toward vaccination in pregnancy, pertussis, and pertussis vaccination during pregnancy among pregnant women in Hong Kong. 61
33426768 2021
14
Progress of public health policy regarding global infectious diseases over the past decade in Japan. 61
33472748 2021
15
Heterologous boosting of nonrelated toxoid immunity during acute Puumala hantavirus infection. 61
33678453 2021
16
Post-Translational Protein Deimination Signatures in Plasma and Plasma EVs of Reindeer (Rangifer tarandus). 61
33805829 2021
17
Lipid binding by the N-terminal motif mediates plasma membrane localization of Bordetella effector protein BteA. 61
33789161 2021
18
Oxytocin Downregulates the CaV1.2 L-Type Ca2+ Channel via Gi/cAMP/PKA/CREB Signaling Pathway in Cardiomyocytes. 61
33806201 2021
19
Titration of myelin oligodendrocyte glycoprotein (MOG) - Induced experimental autoimmune encephalomyelitis (EAE) model. 61
33189793 2021
20
Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model. 61
33812087 2021
21
Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report. 61
33752624 2021
22
Nanomotion Detection-Based Rapid Antibiotic Susceptibility Testing. 61
33801939 2021
23
Free fatty acid receptor 4 inhibitory signaling in delta cells regulates islet hormone secretion in mice. 61
33484949 2021
24
Primary Care Use Among Commercially Insured Adolescents: Evidence From the 2018 Healthcare Effectiveness Data and Information Set. 61
33223362 2021
25
Impact of campaign-style delivery of routine vaccines: a quasi-experimental evaluation using routine health services data in India. 61
33734362 2021
26
Levels of vaccination coverage among HIV-exposed children in China: a retrospective study. 61
33648599 2021
27
Pharmacists' views and desires regarding pharmacist administration of vaccines in New Zealand. 61
33729528 2021
28
Repeated Dose Toxicity Study and Developmental and Reproductive Toxicology Studies of a Respiratory Syncytial Virus Candidate Vaccine in Rabbits and Rats. 61
33517807 2021
29
Maternal Self-Report of Tdap Vaccination During Pregnancy Correlates with Patient-Specific Electronic Medical Records. 61
33745997 2021
30
Fingolimod inhibits glutamate release through activation of S1P1 receptors and the G protein βγ subunit-dependent pathway in rat cerebrocortical nerve terminals. 61
33428887 2021
31
Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™). 61
33541794 2021
32
Transient Probst Bundle Diffusion Restriction: An Acute Encephalopathy Equivalent to Clinically Mild Encephalopathy with a Reversible Splenial Lesion. 61
33642486 2021
33
Investigation of a pertussis outbreak and comparison of two acellular booster pertussis vaccines in a junior school in South East England, 2019. 61
33769247 2021
34
Autoimmune experimental orchitis and chronic glomerulonephritis with end stage renal disease are controlled by Cgnz1 for susceptibility to end organ damage. 61
33482358 2021
35
Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction. 61
33770235 2021
36
Isovaleric acid ameliorates ovariectomy-induced osteoporosis by inhibiting osteoclast differentiation. 61
33768674 2021
37
Molecular Basis for Bordetella pertussis Interference with Complement, Coagulation, Fibrinolytic, and Contact Activation Systems: the Cryo-EM Structure of the Vag8-C1 Inhibitor Complex. 61
33758081 2021
38
BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies. 61
33711798 2021
39
Seroepidemiology of pertussis in China: A population-based, cross-sectional study. 61
33642160 2021
40
Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019. 61
33805681 2021
41
Pertussis Toxin Inhibits Encephalitogenic T-Cell Infiltration and Promotes a B-Cell-Driven Disease during Th17-EAE. 61
33805762 2021
42
Systems view of Bordetella pertussis booster vaccination in adults primed with whole-cell vs. acellular vaccine. 61
33690224 2021
43
Knowledge, attitudes, and practices associated with pertussis vaccination during pregnancy: Japan, 2016-2017. 61
33790066 2021
44
The Path to New Pediatric Vaccines against Pertussis. 61
33807962 2021
45
Pertussis in early life: underdiagnosed, severe, and risky disease. A seven-year experience in a pediatric tertiary-care hospital. 61
32755440 2021
46
Seroprotection for Diphtheria, Pertussis, Tetanus and Measles in Children With Nephrotic Syndrome. 61
33713058 2021
47
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom. 61
33647770 2021
48
Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. 61
32845735 2021
49
Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review. 61
33734002 2021
50
Isolate-Based Surveillance of Bordetella pertussis, Austria, 2018-2020. 61
33622477 2021

Variations for Pertussis

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Pathways for Pertussis

Pathways related to Pertussis according to KEGG:

36
# Name Kegg Source Accession
1 Pertussis hsa05133

GO Terms for Pertussis

Sources for Pertussis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....